
CagriSema in Women: 25% Weight Loss Across Menopause Stages
Women in Novo Nordisk’s big CagriSema trial lost 25.0% of their body weight on average after 68 weeks, versus 3.0% on placebo, according to two new analyses presented on October 20, 2026 at The Menopause Society annual meeting in San Diego. The results held up across menopause stages, from 26.7% before menopause to 23.1% after it. The honest fine print: these are after-the-fact (post hoc) analyses using a best-case way of counting, and CagriSema is still not FDA-approved, with a decision expected in Q4 2026.
Key facts
- Who: 2,309 women from REDEFINE 1, a 68-week phase 3 trial of 3,417 adults with obesity or overweight and no type 2 diabetes. About two-thirds of the trial were women.
- Main result: 25.0% average weight loss on CagriSema 2.4 mg / 2.4 mg vs 3.0% on placebo at week 68 (efficacy estimand, Novo, Oct 20, 2026).
- By menopause stage (1,902 women): 26.7% premenopausal, 24.8% perimenopausal, 23.1% postmenopausal, vs 2.1%, 1.7% and 2.6% on placebo.
- Waist: 20.5 cm smaller on average on CagriSema vs 4.7 cm on placebo; 68.7% of women on CagriSema lost at least 20% of body weight.
- Status, as of Oct 2026: investigational, filed with the FDA in December 2025, decision expected in Q4 2026.
What is CagriSema, quickly?
CagriSema is a once-weekly injection that combines two peptides: semaglutide, the GLP-1 medicine in Wegovy, and cagrilintide, a long-acting copy of amylin, a hormone released with insulin that helps signal fullness after meals. We covered the main trials and the September EASD data in our CagriSema 2026 overview. This post is only about the new results in women.
What did the new analyses find?
Novo ran two analyses of women in REDEFINE 1.
Analysis 1: all women. The trial included groups on CagriSema, on each of its two parts alone, and on placebo. That lets you see what the pairing adds:
| Group (women) | Weight change at 68 weeks | Waist change | Lost 20% or more |
|---|---|---|---|
| CagriSema 2.4 / 2.4 mg (1,441) | -25.0% | -20.5 cm | 68.7% |
| Semaglutide 2.4 mg alone (199) | -19.0% | -17.4 cm | 38.0% |
| Cagrilintide 2.4 mg alone (208) | -13.4% | -11.7 cm | 17.9% |
| Placebo (461) | -3.0% | -4.7 cm | 1.8% |
Average starting weight was about 100 to 102 kg (roughly 220 to 225 lb) in every group. On CagriSema, 93.3% of women lost at least 10% of their body weight.
Analysis 2: by menopause stage. Among 1,902 women grouped by stage, average weight loss on CagriSema was 26.7% in premenopausal women (408 on CagriSema), 24.8% in perimenopausal women (256) and 23.1% in postmenopausal women (530). Placebo groups lost under 3% at every stage. Women on hormone therapy were analyzed separately.
Why menopause is the interesting part
A lot of women gain weight as they move through menopause, which is the reason Novo gave for looking at this. Here, results were strong at every stage. Weight loss was a bit lower after menopause, but still above 23% on average. The study’s lead author, Maria D. Hurtado Andrade of Mayo Clinic, said the numerical differences between groups “highlight the need for further research” on how reproductive aging affects weight loss.
The fine print, told plainly
Good results, but read them for what they are:
- Post hoc means after the fact. Both analyses were done after the trial ended. Novo calls them exploratory and hypothesis-generating. The p-values were not adjusted for running many comparisons, and no formal test checked whether women respond differently than men.
- Best-case counting. The 25.0% uses the “efficacy estimand,” which estimates what happens if everyone stays on the drug and uses no other weight-loss treatment. Counting everyone who started, the full trial showed 20.4%. Among people who stayed on treatment, the full trial showed 22.7%, below the 25% Novo had once targeted, per Reuters.
- Menopause stage was estimated. Stage was assigned afterward from age, medical history and recorded symptoms. It was not staged in advance or confirmed with hormone tests.
- Side effects are common. In REDEFINE 1, gastrointestinal effects hit 79.6% of people on CagriSema vs 39.9% on placebo: nausea 55% vs 12.6%, constipation 30.7% vs 11.6%, vomiting 26.1% vs 4.1%. Most were mild to moderate and passed with time. 5.9% stopped CagriSema because of side effects vs 3.5% on placebo.
How does it compare?
Inside this trial, CagriSema beat semaglutide alone in women by about 6 percentage points (25.0% vs 19.0%), which is the clearest sign the amylin half adds something. Comparing with other drugs’ trials is trickier, because populations and counting methods differ. For context on the approved weekly shots, see semaglutide vs tirzepatide. Lilly is testing its own amylin pairing too, covered in our EloraTZP results.
When could CagriSema be available?
Novo filed with the FDA in December 2025 and expects a decision in Q4 2026. Until then, CagriSema is investigational: it is only available inside clinical trials, and there is no approved compounded version. Anything sold online as “CagriSema” today is not an approved product. For where unapproved peptides stand legally, see our legal status tracker.
What it means for you
This is good news for women with obesity, including those going through or past menopause: one of the next weekly options looks strong at every stage, and an FDA decision is close. It is not approved yet, these specific numbers come from exploratory analyses, and the stomach side effects are real. Women curious about it can talk to a licensed provider about the approved options available today and about whether a clinical trial or a future approval might fit. Our GLP-1 price tracker helps compare the approved options.
Sources
- Novo Nordisk: CagriSema associated with 25% weight loss on average for women, post hoc analyses of REDEFINE 1 (Oct 20, 2026)
- Reuters via WMBD: Novo’s CagriSema helped women lose 25% of weight on average, analysis shows (Oct 20, 2026)
- Novo Nordisk: CagriSema filed for FDA approval (Dec 18, 2025)
- Novo Nordisk: REDEFINE 1 published in NEJM, 22.7% mean weight reduction (June 22, 2025)
Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.